What non‑antibiotic alternatives are available for treating Clostridioides difficile infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Non-Antibiotic Alternatives for Clostridioides difficile Infection

For recurrent CDI, fecal microbiota-based therapies (FMT, fecal microbiota spores live-brpk, or fecal microbiota live-jslm) are the primary non-antibiotic alternatives and should be offered after a second recurrence (third CDI episode). 1, 2

Primary Non-Antibiotic Options

Fecal Microbiota-Based Therapies

These are the only evidence-based non-antibiotic alternatives for CDI treatment:

  • FDA-approved products:
    • Fecal microbiota spores, live-brpk (Vowst)
    • Fecal microbiota, live-jslm (Rebyota)
    • Conventional FMT using appropriately screened donor stool 1

When to use:

  • After completion of standard antibiotic therapy for recurrent CDI (not for active treatment)
  • Following at least one recurrence (second episode), though may be considered after initial infection in high-risk patients 2
  • In patients with severe, fulminant, or treatment-refractory CDI who have recovered 1

Critical timing considerations:

  • Stop CDI antibiotics 1-3 days before conventional FMT (1 day if bowel purge given, 3 days without purge)
  • Use suppressive vancomycin to bridge until FMT administration
  • These therapies prevent recurrence, not treat active infection 1

Bezlotoxumab (Immune-Based Therapy)

This is a monoclonal antibody targeting C. difficile toxin B:

  • Used as adjunctive therapy to prevent recurrence in high-risk adults
  • Given during antibiotic treatment, not as monotherapy
  • Reasonable alternative for patients not interested in fecal microbiota-based therapies 1, 3

Population-Specific Considerations

Immunocompromised Patients

Mildly/moderately immunocompromised: Conventional FMT is suggested after completing antibiotics 1

Severely immunocompromised: FMT is suggested AGAINST, including:

  • Active cytotoxic therapy for malignancies
  • CAR-T or hematopoietic cell transplant with neutropenia
  • Any neutropenia
  • Severe primary immunodeficiency
  • Advanced HIV (CD4 <200/mm³) 1

Severe/Fulminant CDI

Multi-dose conventional FMT via lower endoscopy should be considered:

  • For hospitalized patients not responding to antibiotics within 2-5 days
  • Delivered via colonoscopy or flexible sigmoidoscopy (first dose)
  • Repeat FMT typically needed every 3-5 days based on response
  • NOT advised: FDA-approved products (Vowst, Rebyota) have not been studied in severe/fulminant disease 1, 2

Contraindications to FMT in severe disease:

  • Bowel perforation
  • Obstruction
  • Severe immunocompromise 1

What Does NOT Work as Non-Antibiotic Therapy

Probiotics

The AGA recommends probiotics ONLY in clinical trials for CDI treatment. 4

  • Not advised for prevention of initial or recurrent CDI 2
  • Conditional recommendation against use in children with acute infectious gastroenteritis 4
  • No evidence supporting their use in IBD patients with CDI 5

Other Agents to Avoid

  • Cholestyramine and bile acid-binding agents: Should not be used as monotherapy or with vancomycin/fidaxomicin 2
  • Psyllium fiber: Only appropriate after recovery to bulk stools, not during active infection 2

Alternative Antibiotic Strategies (When Non-Antibiotic Options Unavailable)

If patients decline or cannot receive fecal microbiota-based therapies:

  • Vancomycin taper regimen
  • Tapered-pulsed fidaxomicin
  • Prolonged suppressive vancomycin (125 mg daily) for multiple recurrences 1, 2

Critical Pitfalls

Avoid these common mistakes:

  • Using FMT during active infection (must complete antibiotics first)
  • Administering FDA-approved microbiota products in severe/fulminant disease
  • Using probiotics as CDI prevention or treatment
  • Stopping immunosuppression in IBD patients with concurrent CDI 5
  • Performing FMT in severely immunocompromised patients
  • Using nasoenteric tube for FMT in severe disease (aspiration risk) 1

Patients requiring frequent or long-term antibiotics: Carefully consider before proceeding with fecal microbiota-based therapies, as ongoing antibiotics diminish efficacy 1

References

2
Research

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026

3
Research

[Clostridioides difficile infections: Update and therapeutic guidelines].

Geriatrie et psychologie neuropsychiatrie du vieillissement, 2024

Related Questions

Which medications are safe to use for abdominal cramping and diarrhea in a patient with Clostridioides difficile infection?
How should a patient with Clostridioides difficile infection who is NPO be treated?
What is the best treatment for Clostridioides difficile infection in an adult patient who is concurrently receiving antibiotics for another indication?
What is the recommended treatment for an initial Clostridioides difficile infection?
What is the appropriate initial therapy for a patient hospitalized in a rehabilitation center who presents to the emergency department with fever and diarrhea and has stool positive for Clostridioides difficile antigen and toxin?
I am concerned about Clostridioides difficile infection; what signs should I watch for and how should it be managed?
Can hypercortisolism cause poor weight loss or reduced response to glucagon-like peptide-1 (GLP-1) receptor agonist therapy (e.g., tirzepatide)?
What is the appropriate dosage of Lyrica (pregabalin) for a 71-year-old patient with an estimated glomerular filtration rate (eGFR) of 59 mL/min/1.73 m²?
What is the clinical significance of a slightly elevated red blood cell distribution width (RDW 19.1%) indicating mild anisocytosis in the setting of an otherwise normal complete blood count?
What are the appropriate methimazole dosing regimens and safety considerations for adults, children, elderly, and pregnant patients with Graves disease?
What are the recommended dosing and adjustment guidelines for methimazole in adult patients with Graves disease, including monitoring parameters and special considerations for pregnancy, the elderly, and adverse effects?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.